A groundbreaking RNA-based therapy aims to transform the treatment of heart damage following a heart attack by promoting actual regeneration of cardiac tissue.
While restoring blood flow is critical, the heart often suffers permanent damage because lost muscle cells do not regenerate, leaving many patients at risk of heart failure.
The new approach, published in Science, turns the body into a “drug factory.” An RNA injection into muscle tissue instructs cells to produce an inactive therapeutic molecule, which is activated only upon reaching the heart.
In preclinical studies, a single injection reduced scar tissue and improved heart function in animal models. The therapy works by boosting atrial natriuretic peptide (ANP), a hormone linked to heart regeneration that declines with age.
Using self-amplifying RNA, the treatment can remain effective for up to a month, potentially eliminating the need for invasive procedures.
Researchers are now preparing early-stage human trials, with hopes that the method could extend to other conditions, including kidney disease and hypertension.